Gland Pharma’s ₹6.29 Crore GST Dispute: What Investors Need to Know Introduction

Introduction

In the dynamic world of India’s pharmaceutical sector, tax disputes under the Goods and Services Tax (GST) regime are not uncommon, often arising from interpretations of export transactions and credit adjustments. Gland Pharma Limited, a Hyderabad-based leader in generic injectables, recently made headlines after receiving a GST demand notice. This blog explores the details of the case, the company’s stance, and its potential implications, drawing from the latest updates as of March 9, 2026.

Company Overview

Gland Pharma, established in 1978, specializes in complex injectables, including oncology and peptide products. With a global presence in over 60 countries and manufacturing facilities compliant with US FDA and EU GMP standards, the company has seen robust growth. In Q3 FY26 (ended December 31, 2025), it reported a 22% year-on-year revenue increase to ₹16,954 million, driven by strong demand in the US and Europe. The acquisition of Cenexi has further bolstered its European operations, contributing €50 million in Q3 revenue—a 39% jump.

The GST Demand Details

On March 5, 2026, the Deputy Commissioner (ST)-V of the GST Department in Telangana issued an order to Gland Pharma for the financial year 2019-20. The demand totals approximately ₹6.29 crore, broken down as follows:

Tax: ₹5,03,51,468
Penalty: ₹1,25,87,867
Plus applicable interest

The issues stem from:

Reclassification of ₹4,57,79,447 in export turnover as domestic sales, attracting GST.
Discrepancies in credit notes for ₹45,72,022 related to exports, possibly due to inadequate documentation or adjustments for returns and discounts.

This order was received via email on March 6, 2026, and disclosed promptly under SEBI regulations.

Such disputes highlight ongoing challenges in GST compliance for export-oriented firms, where zero-rated supplies require stringent proof to avoid tax liabilities.

Company’s Response and Outlook

Gland Pharma has described the demand as “unjustified” based on its review of facts and laws. The company intends to file an appeal with the appellate authority, expressing confidence in a positive outcome. It has emphasized that the matter poses no material risk to its financials, operations, or activities.

This isn’t isolated; similar GST notices have affected peers like GlaxoSmithKline. Gland Pharma’s strong balance sheet evident from its Q3 profit surge provides resilience. For FY26, it anticipates capex of ₹2,500 million for its base business and €25 million for Cenexi.

Market Reaction and Stock Performance

The announcement led to a dip in Gland Pharma’s shares. On March 6, 2026, the stock closed at ₹1,669, down 2.19%. By midday on the same day, it was quoting at ₹1,676.60, reflecting a 1.75% decline amid a broader Nifty Pharma index drop. Over the past month, shares have eased by about 11%, though the one-year performance shows a 28.86% tumble against Nifty’s 9.07% gain.

Social media buzz on X (formerly Twitter) echoes the news, with posts from stock trackers highlighting the appeal plans and minimal impact.

Broader Implications for the Pharma Sector

GST disputes like this underscore the need for clearer guidelines on export taxation, especially as India’s pharma exports grow. With recent GST Council decisions reducing rates on cancer drugs to 5%, the sector is adapting to a more patient-friendly regime. For Gland Pharma, this could be a minor hurdle in an otherwise upward trajectory, bolstered by USFDA approvals and expansion.

Investors should monitor the appeal’s progress and upcoming Q4 results. While short-term volatility persists, the company’s fundamentals remain solid.

Disclaimer: This is not investment advice. Consult professionals for financial decisions. Market data as of March 9, 2026.